GlaxoSmithKline

The eClinical solutions market is projected to grow by USD 12.77 billion from 2024-2028, driven by increasing clinical trials and outsourcing trends, despite rising costs. Key players include Advarra Inc., Aixial, Anju Software Inc., and others.

Muna Therapeutics, a biotech company, collaborates with GSK to analyze brain tissue samples to identify new targets for Alzheimer’s drugs, potentially worth hundreds of millions. GSK provides €33.5 million upfront and up to €140 million in milestone payments per target. Muna will expand its dataset and find molecular switches, while GSK leads drug development and commercialization. Muna, formed in 2020, merges with K5 Therapeutics and raises $73 million. GSK, returning to neuroscience, sees Muna’s technology as key to understanding neurodegenerative diseases.

Micaela F. Bayard, MD, discusses the inclusion of patient voices in rheumatoid arthritis clinical trials at ACR Convergence 2024, emphasizing the need for diversity and representation.

EFPIA highlights EU's roadmap for precision oncology to address rising cancer burden, despite forecasted mortality rate declines. Stakeholder roundtable in Brussels aims to improve personalized cancer treatment. EU initiatives, including AI-powered cancer care and the DigiONE pilot, aim to advance precision medicine. A gold-standard cancer data management system is necessary for innovative precision medicine access, emphasizing standardized data formats, robust privacy, and professional education.

The Biden administration's proposals targeting patents as the cause of high drug prices may harm the complex network of firms, researchers, and investors needed to bring new drugs to market. The FTC challenged over 400 patents listed in the Orange Book, aiming to accelerate generic drug entry and lower prices, but this undermines the U.S. pharmaceutical industry's competitive edge globally. The patent system's erosion could disadvantage the U.S. biopharmaceutical industry, especially as China's industry rapidly advances. Understanding the roles of generic drugs, the FTC's challenges, and the impact on U.S. innovation and competitiveness is crucial for advancing policies that secure the future of the U.S. innovative industry.

Precision medicine in cancer therapy is advancing, with targeted diagnostics and treatments becoming common in developed countries. Startups like Creasallis and Concr aim to address unmet needs, improving antibody therapies and developing predictive tools for cancer treatments. Both CEOs, Zahra Jawad and Irina Babina, discussed their journeys and goals in precision medicine.

DelveInsight's report on the Respiratory Syncytial Virus (RSV) market forecasts trends and epidemiology in the U.S., EU4, UK, and Japan until 2034. Key companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies in development include Nirsevimab, RSVpreF Vaccine, and others. The market is expected to grow due to increasing incident cases and upcoming therapies, despite current treatment limitations.

Respiratory syncytial virus (RSV) market report by DelveInsight covers epidemiology, market forecast, and key companies like Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others. Promising therapies include Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others.